pipeline-prospector-insert-v1
X

Find Novel Drugs for Infections and Infectious Diseases under Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 2019-nCoV vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            The Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Leronlimab

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            Leronlimab has shown no drug-related serious adverse events in nine clinical trials with more than 800 patients and has been previously used in combination with protease inhibitors used in HIV therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trans HSC (CD34+)

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: L2P Research

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 23, 2020

            Details:

            The partnership highlight the product line dealing with CD34+ cells and Humanized mouse models, both firms use the framework of collaborative business development to tackle competition and efficiency of research-grade stem cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): INO-4800

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Coalition for Epidemic Preparedness Innovations

            Deal Size: $9.0 million Upfront Cash: Undisclosed

            Deal Type: Funding January 23, 2020

            Details:

            This initial CEPI funding will support Inovio's preclinical and clinical development through Phase 1 human testing of INO-4800, its new coronavirus vaccine matched to the outbreak strain.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 23, 2020

            Details:

            The programmes will leverage rapid response platforms already supported by CEPI. The aim is to advance nCoV-2019 vaccine candidates into clinical testing as quickly as possible.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Phage-based therapy

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Department of Defense

            Deal Size: $10.2 million Upfront Cash: Undisclosed

            Deal Type: Funding January 15, 2020

            Details:

            The award is designated to conduct a clinical trial, with the goal of making PhageBank phage therapy available to treat multidrug-resistant (MDR) and complicated infections.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CHO-DG44

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Serum Institute of India Private Limited

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 08, 2020

            Details:

            Under the terms of the collaboration, Aragen is set to provide Serum with high expressing cell lines enabling Serum to quickly move their RapTrâ„¢ platform forward into Manufacturing.